Siemens Healthineers Shares Plunge Amidst Market Volatility and Pending Accela Clearance

Siemens Healthineers has encountered turbulence in recent sessions as investors weigh its imaging momentum against pending Accela clearance. The stock dropped 2.1% to close at EUR 37.83, influenced by a broader market mood soured by weak eurozone inflation figures and interest rate concerns.

The pullback continued into the next trading day, with the stock giving up another 1.2% to change hands at EUR 38.16. Investors are questioning whether this is a buying opportunity or the start of a deeper slide for the company's shares.

The outcome hinges largely on Siemens Healthineers' imaging division, where management expects a visible acceleration in the final quarter to bring its full-year goals within reach. Organic revenue growth of up to 4% and adjusted earnings per share between EUR 2.35 and EUR 2.45 are on the table for the current fiscal year.

The expected year-end sprint should be powered by imaging, where revenue pushed out of the prior quarter and a steady scanner business will provide lift. Precision therapy is also forecast to advance, though the diagnostics unit is still seen contracting. At the operating margin level, a sequential improvement looks likely, even if persistent cost pressure could take some of the shine off the gains.